Kynam Capital Management, LP reported 33 positions worth $1.81B for the quarter ended Sep 30, 2026, down 0.2% on the prior quarter. It opened 4 new positions, added to 8, trimmed 6 and exited 2. Its largest holding is Legend Biotech Corp at 10.1% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| LEGN Legend Biotech Corp | +6.15M | +205.0% | $122.39M | 10.08% |
| SMMT Summit Therapeutics Inc. | +1.80M | +150.0% | $30.44M | 2.81% |
| BEAM Beam Therapeutics Inc. | +1.09M | +38.5% | $26.73M | 5.33% |
| SRZN Surrozen, Inc. | +486.3K | – | $15.65M | 0.866% |
| XENE Xenon Pharmaceuticals Inc. | +280.0K | – | $10.41M | 0.577% |
| EVMN Evommune, Inc. | +1.20M | – | $9.91M | 0.549% |
| PHVS Pharvaris N.V. | +163.0K | +24.6% | $5.17M | 1.45% |
| COGT Cogent Biosciences, Inc. | +125.2K | +3.4% | $4.01M | 6.72% |
| HROW Harrow, Inc. | +124.7K | – | $3.84M | 0.213% |
| VERA Vera Therapeutics, Inc. | +109.9K | +3.8% | $3.55M | 5.36% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PCVX Vaxcyte, Inc. | -314.4K | -10.8% | $17.89M | 8.22% |
| INSM INSMED Inc | -100.0K | -100.0% | $10.66M | Exited |
| RLAY Relay Therapeutics, Inc. | -548.5K | -16.6% | $9.90M | 2.75% |
| CLDX Celldex Therapeutics, Inc. | -256.9K | -4.8% | $8.32M | 9.09% |
| VRDN Viridian Therapeutics, Inc.DE | -305.9K | -4.7% | $6.30M | 7.01% |
| CTMX CytomX Therapeutics, Inc. | -562.4K | -2.6% | $1.53M | 3.18% |
| CADL Candel Therapeutics, Inc. | -96.7K | -100.0% | $996.43K | Exited |
| PRLD Prelude Therapeutics Inc | -103.1K | -4.3% | $403.25K | 0.501% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | LEGN Legend Biotech Corp | Healthcare | 9.15M | $182.08M | 10.08% | +6.15M | +205.0% | Added | 4.72% |
| 2 | CLDX Celldex Therapeutics, Inc. | Healthcare | 5.07M | $164.19M | 9.09% | -256.9K | -4.8% | Reduced | 6.45% |
| 3 | SNDX Syndax Pharmaceuticals Inc | Healthcare | 8.15M | $153.24M | 8.48% | +100.0K | +1.2% | Added | 9.06% |
| 4 | PCVX Vaxcyte, Inc. | Healthcare | 2.61M | $148.39M | 8.22% | -314.4K | -10.8% | Reduced | 1.75% |
| 5 | VRDN Viridian Therapeutics, Inc.DE | Healthcare | 6.15M | $126.59M | 7.01% | -305.9K | -4.7% | Reduced | 5.42% |
| 6 | COGT Cogent Biosciences, Inc. | Healthcare | 3.79M | $121.43M | 6.72% | +125.2K | +3.4% | Added | 2.18% |
| 7 | TVTX Travere Therapeutics, Inc. | Healthcare | 2.00M | $117.76M | 6.52% | 0 | 0.0% | Unchanged | 2.09% |
| 8 | URGN UroGen Pharma Ltd. | Healthcare | 2.43M | $98.90M | 5.48% | 0 | 0.0% | Unchanged | 4.81% |
| 9 | VERA Vera Therapeutics, Inc. | Healthcare | 3.00M | $96.87M | 5.36% | +109.9K | +3.8% | Added | 4.16% |
| 10 | BEAM Beam Therapeutics Inc. | Healthcare | 3.93M | $96.18M | 5.33% | +1.09M | +38.5% | Added | 3.76% |
| 11 | CTMX CytomX Therapeutics, Inc. | Healthcare | 21.14M | $57.50M | 3.18% | -562.4K | -2.6% | Reduced | 9.65% |
| 12 | MBX MBX Biosciences, Inc. | Healthcare | 934.8K | $54.80M | 3.03% | 0 | 0.0% | Unchanged | 1.88% |
| 13 | SMMT Summit Therapeutics Inc. | Healthcare | 3.00M | $50.73M | 2.81% | +1.80M | +150.0% | Added | 0.38% |
| 14 | RLAY Relay Therapeutics, Inc. | Healthcare | 2.75M | $49.66M | 2.75% | -548.5K | -16.6% | Reduced | 1.25% |
| 15 | CGEM Cullinan Therapeutics, Inc. | Healthcare | 3.11M | $47.80M | 2.65% | 0 | 0.0% | Unchanged | 4.8% |
Tip. Select a row to see that position’s full history at Kynam Capital Management.
As of its Q3 2026 13F filing, Kynam Capital Management, LP’s five largest positions were Legend Biotech Corp (LEGN) at 10.1%, Celldex Therapeutics, Inc. (CLDX) at 9.1%, Syndax Pharmaceuticals Inc (SNDX) at 8.5%, Vaxcyte, Inc. (PCVX) at 8.2%, Viridian Therapeutics, Inc.DE (VRDN) at 7.0% of the reported portfolio.
Kynam Capital Management, LP reported a 13F portfolio worth $1.81B across 33 positions for Q3 2026. That is down 0.2% from the previous quarter.
Its largest purchases by value were Legend Biotech Corp ($122.39M), Summit Therapeutics Inc. ($30.44M), Beam Therapeutics Inc. ($26.73M). It opened 4 new positions.
Its largest sales by value were Vaxcyte, Inc. ($17.89M), INSMED Inc ($10.66M), Relay Therapeutics, Inc. ($9.90M). It exited 2 positions entirely.
From the Form 13F-HR reports Kynam Capital Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.